CYP
data caveat$85M7mo
Cynata Therapeutics
Biotechnology · Cell therapy
Clinical-stage biotech developing off-the-shelf iPSC-derived mesenchymal stem cell therapies via its Cymerus platform, with Phase 2/3 trials in GvHD and osteoarthritis.
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$2.6M
Dec 2025 4C
Runway
7moCAUTION
Based on Dec 2025 4C
Market Cap
$85M
Burn Rate
$1.2M/qtr
Dec 2025 4C
Shares Outstanding
237M
Pipeline Assets
6
Latest Insight(1)
26 Feb 2026Half YearAppendix 4D & Half-Year Financial Statements
Cash$2.6M·Burn$2.4M/q·OCF$-2.4M
3M Price
CYP.ASX$0.360+14.3% 3M
Low $0.280High $0.395
Pipeline Assets (6)
CYP-006TKdiabetic foot ulcers
Phase 1CYP-006TK (Cymerus MSCs)diabetic foot ulcers
Phase 1CYP-001acute graft-versus-host disease
Phase 2CYP-001 (Cymerus MSCs)acute graft-versus-host disease
Phase 2CYP-004knee osteoarthritis
Phase 3CYP-004 (Cymerus MSCs)knee osteoarthritis
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
3 approved drugs1000 competitor trialsPhase 2+ · Non-ASX
Diabetic Foot Ulcers16 active trials
9 Ph27 Ph1/PHASE2
Knee Osteoarthritis48 active trials
29 Ph219 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
1 paper
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Stem Cell Res Ther2025-12· Cymerus MSCs
Catalysts (4)
CYP-001 Phase 2 aGvHD top-line results
UpcomingConfirmedarrow_upwardHigh30 June 2026
CYP-004 Phase 3 osteoarthritis top-line results (SCUlpTOR)
UpcomingConfirmedarrow_upwardHigh30 June 2026
CYP-001 Phase 2 aGvHD top-line results
UpcomingExpectedarrow_upwardHigh30 June 2026
CYP-004 Phase 3 osteoarthritis top-line results
UpcomingExpectedHigh
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
Clinical Trials(2)
1 activeClinicalTrials.gov ↗
Ph2RecruitingEnrollment stale · 779d
CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)PlaceboCorticosteroids
A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD
Graft Versus Host Disease, Acute
RandomizedQuadruple Blind18 Years+
Primary endpoint Overall response rate (ORR)
Announcements(7)
description
Half YearPSauto_awesome
Appendix 4D & Half-Year Financial Statements26 Feb 2026
expand_more1079KB